Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| IceCure Medical Ltd.ICCM · Entity 8100 | Chief Operating Officer | August 14, 2026 | August 17, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
IceCure Medical Ltd.
Report date August 14, 2026 · Filed August 17, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 146,303 |
Reported balance
After 2026-08-14 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-08-14 · Grant · Acquired 141,483 · Balance 146,303 F1: Represents (i) 141,483 restricted share units ("RSUs") granted on August 14, 2026, 25% of which vest on August 11, 2027, and the remaining 75% vest in twelve equal quarterly installments of 6.25% thereafter, (ii) 2,727 RSUs granted on July 2, 2024, 25% of which vested on July 29, 2026, and the remaining 75% vest in equal quarterly installments of 6.25% thereafter, (iii) 1,447 RSUs granted on November 5, 2025, 25% of which vest on November 5, 2026, and the remaining 75% vest in equal quarterly installments of 6.25% thereafter, and (iv) 646 RSUs granted on March 16, 2026, 25% of which vest on March 16, 2027, and the remaining 75% vest in equal quarterly installments of 6.25% thereafter. Except for the 25% tranche of the RSUs granted on July 2, 2024 that vested on July 29, 2026, all of the foregoing RSUs remain unvested as of August 13, 2026. The holdings described in clauses (ii) through (iv) have been adjusted to reflect the Issuer's 1-for-30 reverse share split. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents (i) 141,483 restricted share units ("RSUs") granted on August 14, 2026, 25% of which vest on August 11, 2027, and the remaining 75% vest in twelve equal quarterly installments of 6.25% thereafter, (ii) 2,727 RSUs granted on July 2, 2024, 25% of which vested on July 29, 2026, and the remaining 75% vest in equal quarterly installments of 6.25% thereafter, (iii) 1,447 RSUs granted on November 5, 2025, 25% of which vest on November 5, 2026, and the remaining 75% vest in equal quarterly installments of 6.25% thereafter, and (iv) 646 RSUs granted on March 16, 2026, 25% of which vest on March 16, 2027, and the remaining 75% vest in equal quarterly installments of 6.25% thereafter. Except for the 25% tranche of the RSUs granted on July 2, 2024 that vested on July 29, 2026, all of the foregoing RSUs remain unvested as of August 13, 2026. The holdings described in clauses (ii) through (iv) have been adjusted to reflect the Issuer's 1-for-30 reverse share split.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 14, 2026 Filed Aug 17, 2026 12:16 UTC | IceCure Medical Ltd. ICCM · Entity 8100 | GrantOrdinary Shares | 141,483 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-26-090509 · ownership.xml · nonDerivative · entry 1 Levav Shay · CIK 0002047217 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 146,303 F1 · balance_after: Represents (i) 141,483 restricted share units ("RSUs") granted on August 14, 2026, 25% of which vest on August 11, 2027, and the remaining 75% vest in twelve equal quarterly installments of 6.25% thereafter, (ii) 2,727 RSUs granted on July 2, 2024, 25% of which vested on July 29, 2026, and the remaining 75% vest in equal quarterly installments of 6.25% thereafter, (iii) 1,447 RSUs granted on November 5, 2025, 25% of which vest on November 5, 2026, and the remaining 75% vest in equal quarterly installments of 6.25% thereafter, and (iv) 646 RSUs granted on March 16, 2026, 25% of which vest on March 16, 2027, and the remaining 75% vest in equal quarterly installments of 6.25% thereafter. Except for the 25% tranche of the RSUs granted on July 2, 2024 that vested on July 29, 2026, all of the foregoing RSUs remain unvested as of August 13, 2026. The holdings described in clauses (ii) through (iv) have been adjusted to reflect the Issuer's 1-for-30 reverse share split. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.